D.A. Davidson & CO. Boosts Stake in Axon Enterprise, Inc $AXON

D.A. Davidson & CO. increased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 58.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,144 shares of the biotechnology company’s stock after purchasing an additional 5,958 shares during the quarter. D.A. Davidson & CO.’s holdings in Axon Enterprise were worth $9,050,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of AXON. Evergreen Capital Management LLC lifted its holdings in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Axon Enterprise by 1.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after acquiring an additional 19 shares during the last quarter. Synergy Financial Group LTD lifted its stake in shares of Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 19 shares in the last quarter. Certuity LLC boosted its holdings in Axon Enterprise by 5.1% in the fourth quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 23 shares during the last quarter. Finally, Pure Financial Advisors LLC grew its stake in Axon Enterprise by 6.7% during the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 23 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the transaction, the executive directly owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 68,989 shares of company stock valued at $36,016,932 over the last ninety days. Insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Down 0.4%

AXON stock opened at $612.83 on Friday. The firm has a market cap of $49.78 billion, a price-to-earnings ratio of 254.29, a PEG ratio of 12.56 and a beta of 1.39. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $794.29. The firm has a fifty day moving average price of $526.06 and a two-hundred day moving average price of $474.40. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. During the same period in the previous year, the business posted $2.12 EPS. The company’s quarterly revenue was up 35.3% on a year-over-year basis. Research analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AXON shares. Piper Sandler upped their target price on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. UBS Group lifted their price target on shares of Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.